ERP023579 PRJEB21338 ena-STUDY-KAZAN (VOLGA REGION) FEDERAL UNIVERSITY-18-06-2017-20:18:25:181-1662 Shotgun metagenomic data of fecal microbiota of patients with H. pylori infection before and after eradication therapy Helicobacter pylori was reported to be one of the most common reasons of gastric diseases. According to the Maastricht V Consensus, patients with H. pylori infection are prescribed a two-week eradication therapy consisted of 2 types of broad spectrum antibiotics. Such treatment can negatively affect the gut microbiota of patients by decreasing the number of members of the normal bacterial flora. The metagenomic analisys of the fecal microbiota of patients with H. pylori infection at 3 time points (before the start of the eradication therapy, immediately after the therapy and several weeks after the end of treatment) could help to reveal the taxonomic and functional changes in intestinal microflora and to detect molecular markers of gastrointestinal diseases pathogenesis. Bacterial community of human fecal microbiota of patients with H. pylori infection Helicobacter pylori was reported to be one of the most common reasons of gastric diseases. According to the Maastricht V Consensus, patients with H. pylori infection are prescribed a two-week eradication therapy consisted of 2 types of broad spectrum antibiotics. Such treatment can negatively affect the gut microbiota of patients by decreasing the number of members of the normal bacterial flora. The metagenomic analisys of the fecal microbiota of patients with H. pylori infection at 3 time points (before the start of the eradication therapy, immediately after the therapy and several weeks after the end of treatment) could help to reveal the taxonomic and functional changes in intestinal microflora and to detect molecular markers of gastrointestinal diseases pathogenesis. ENA-FIRST-PUBLIC 2017-06-22 ENA-LAST-UPDATE 2017-06-18